By Michelle NicholsAUSTIN, Texas (AP) A new Chinese drug has claimed a major breakthrough in treating a rare form of the asthmatic condition that’s killed millions worldwide.
The Chinese company, Zhejiang Biologics, announced Thursday it had created an inhibitor that works like an antibiotic that can be injected into the airways to help relieve symptoms.
The drug, called Zhewangitang, has been approved by the U.S. Food and Drug Administration for use in the treatment of patients with asthma.
The product is being tested by the Chinese government and pharmaceutical companies in more than 30 countries.
China’s leading lung-cancer drugmaker, CSC Pharma, is testing it in two more countries.
The U.K. also plans to use Zheyangitang in lung cancer patients.
In recent years, China has been aggressively expanding its efforts to develop treatments for the deadly condition known as acute myeloid leukemia.
More than 40 million Chinese have died from the disease.
The company is making significant progress on several fronts, including finding a way to stop cells from multiplying in the lungs, which causes acute myalgias.
China has also begun treating patients with the virus, a treatment that has helped the country beat the spread of the coronavirus.
But China has also been plagued by soaring COVID-19 infections and deaths.
The U.N. agency that monitors deaths from the virus says China has more than tripled the number of COVID deaths in China since 2014, and the country is still at the bottom of the list of countries with the most deaths.
China is also trying to figure out how to control COVID, and has begun using a “counter-stacking” strategy to try to control cases in its hospitals.
The government has announced plans to increase COVID screenings and treatments in hospitals, but some hospitals have not seen any significant benefit.